Evaluation of PSMA Antagonist Produced by Two Different Methods
Status:
Enrolling by invitation
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Patients with metastatic prostate cancer will undergo two protocol 68Ga-PET scans within
24-48 hours with 68Ga-PSMA-cyclotron and 68Ga-PSMA-generator radiotracers. The goal of the
study is to evaluate repeatability and equivalence across the different 68Ga-PSMA production
methods. This research study is being conducted to assess whether the PET/CT imaging results,
as generated from the two different 68Ga production methods, are equivalent.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)